Active Pharmaceuticals Ingredients Lamivudine CAS 134678-17-4 For Liver And Gallbladder Diseases CAS NO.134678-17-4

• quick detail of active pharmaceutical ingredients lamivudine :

product name:lamivudine

synonyms:

(-)-bch-189;(-)-beta-l-2',3'-dideoxy-3'-thiacytidine;(-)-b-l-2',3'-dideoxy-3'-thiacytidine;(2r-cis)-4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1h)-pyrimidinone;2'-deoxy-3'-thiacytidine;4-amino-1-((2r,5s)-2-hydroxymethyl-[1,3]oxathiolan-5-yl)-1h-pyrimidin-2-one;3tc;3'-thia-2',3'-dideoxycytidine;

cas: 134678-17-4;

mf: c8h11n3o3s;

mw:229.26.

• description ofactive pharmaceutical ingredientslamivudine:

1. lamivudine is a new antiviral drug, belonging to nucleoside reverse transcriptase inhibitors, having a strong inhibitory effect in vitro and animal experimental infection of hepatitis b virus (hbv), can inhibit the synthesis of hiv virus; the drug produced by the glaxosmithkline co.

2. in the early 90s, they are used for the treatment of aids drugs in europe and north american countries. in the middle of the 1990 medical experts found that they have inhibition to hepatitis b virus dna, in 1998 the united states food and drug administration (fda) approved the first drug for treatment of hepatitis b treatment. in china, the state food and drug administration approved the drug import mainly used as medicine in the treatment of hepatitis b.

3. lamivudine is the only proven to delay hepatitis cirrhosis progress, fewer side effects, less cost of medication, currently has 2 million of the country's hepatitis b patients are using.

4. lamivudine can be metabolized to lamivudine three phosphate in hbv infection cells and normal cells, it is the active form of lamivudine, both inhibitors of hbv polymerase, and is polymerase substrate.

5. lamivudine three phosphate incorporation into viral dna chain, can block the synthesis of viral dna, and does not interfere with normal cell deoxynucleoside metabolism, having weak inhibition to mammalian dna polymerase alpha and beta, almost no effect on mammalian cell dna content, and without obvious toxicity to the structure of mitochondria, content and function of dna.

6. for serum hbv-dna detection results of most hepatitis b patients showed that lamivudine can rapidly inhibit the replication of hbv, its inhibitory effect lasted for the entire treatment process. at the same time the serum transaminase decreased to normal, long-term use can significantly improve the liver necrosis and inflammatory changes in relieve or prevent liver fibrosis.

• medical usage of active pharmaceutical ingredientslamivudine:

lamivudine has been used for treatment of chronic hepatitis b at a lower dose than for treatment of hiv/aids. it improves the seroconversion of e-antigen positive hepatitis b and also improves histology staging of the liver.

long-term use of lamivudine leads to emergence of a resistant hepatitis b virus (ymdd) mutant. despite this, lamivudine is still used widely as it is well tolerated.

• technical testing sheet:

coa:

• what kind of patients suitable for use lamivudine

not all patients with hepatitis b are suitable for the use of lamivudine. lamivudine should be applied in the following cases according to the action characteristics of lamivudine and clinical summary of the experience in the application of lamivudine:

(1) hbvdna quantitative detection of moderate positive; hbeag positive; alt increased 2 ~ 10 times.
(2) hbeag negative, but hbvdna was moderately positive (do not take the qualitative pcr results as the standard, to do quantitative measurement), alt increased 2 ~ 10 times. the majority of this situation may be the virus gene mutations in the c region.

not suitable for the use of lamivudine is the main:

(1) hbvdna negative or quantitative determination of <105copies/ml;
(2)with normal alt (mainly refers to the virus asymptomatic hbv carriers (asc); for the past elevated alt, but now alt and ast normal patients, can be temporary not treatment, elevated alt and treated. the patient was not suitable for use, not because lamivudine is harmful to the people, but because of the low effective rate of these patients, does not meet the pharmaceutical economics principle.
lamivudine, like any other drugs, can be used properly to benefit most patients, and inappropriate use will not produce the desired effect, and inappropriate withdrawal may even lead to exacerbations.